

Fasting therapy of Chinese Medicine was put forward by Professor Qin Jian based on the theory of fat and grease from The Yellow Emperors Internal Classi and modified on the basis of Buchinger fasting therapy. Here we try to report a female patient with the chief complaint of arthralgia who was diagnosed as rheumatoid arthritis, non-alcoholic fatty liver disease and suspected type 2 diabetes mellitus, also diagnosed by Chinese medicine with Bi disease of spleen deficiency and phlegm dampness syndrome. After admission, the patient was treated with fasting therapy of Chinese Medicine for a week. Considering that she was in the menstrual period, she was given a very-low-calorie diet during that time. Moreover, she was given L-carnitine injection, health education and traditional Chinese medicine treatment, including foot massage, acupuncture and acupoint application everyday. After discharge, she was asked to take low-calorie diet and modified Linggui Zhugan Decoction for another week. After that, she followed the doctor's instructions for long-term caloric control. A year later, the reexamination showed that her condition was improving.

Keywords / 关键词

Fasting therapy of Chinese Medicine; Rheumatoid arthritis; Type 2 diabetes mellitus; Non-alcoholic fatty liver disease; Bi disease; Spleen deficiency and phlegm dampness syndrome

Related articles / 相关文献

相似文献 作者发文 机构发文 关键词分析

相似文献(说明:与本文内容较接近的文献)

- [1] Pagano S., Alfaiate D., Juillard C. et al. Autoantibodies directed against apolipoprotein-A1 as a potential contributor to non-alcoholic fatty liver disease [J] Atherosclerosis, 2021, 331
- [2] Dalbeni A., Conci S., Valigi T. et al. OC-03Non-alcoholic fatty liver disease and increased risk of incident primary malignant liver tumours: a meta-analysis of observational cohort studies[J] Digestive and Liver Disease, 2021, 53(S4)
- [3] Alessio Aghemo, Cesare Berra, Massimo Colombo Managing Patients with non-alcoholic fatty liver disease: is it really only about Fibrosis?[J] Gastroenterology, 2018, 155(3)
- [4] Nahum Méndez-Sánchez, Alejandro Valencia-Rodríguez Caveats for the implementation of global strategies against non-alcoholic fatty liver disease[J] Journal of Hepatology, 2020, 73(1)
- [5] Dusilova T., Kovar J., Sedivy P. et al. The increase of hepatic fat content after fat consumption is greater in men with non-alcoholic fatty liver disease than in healthy subjects[J] Atherosclerosis, 2020, 315
- [6] Lena Heintz, Robert Holz, Susanne N Weber et al. SAT-303-Liver fibrosis together with PNPLA3 p.I148M variant affects quality of life in patients with non-alcoholic fatty liver disease: prospective liver stiffness-based study[J] Journal of Hepatology, 2019, 70(1)
- [7] B. Cicek, A. Koksal, D. Oguz et al. 579 Ursodeoxycholic acid and gemfibrozil in the treatment of non-alcoholic steatohepatitis: A randomized controlled trial[J] Journal of Hepatology, 2004, 40(S1)
- [8] L. Spadaro, O. Magliocco, D. Spampinato et al. 738 Omega-3 polyunsaturated fatty acids: A pilot trial in non-alcoholic fatty liver disease[J] Journal of Hepatology, 2006, 44(S2)
- [9] Otto Kucera, Pavla Krivakova, Tomas Rousar et al. Model of non-alcoholic fatty liver disease in rats for toxicological studies[J] Toxicology Letters, 2008, 180(S)

[10] Peng Xiaojuan, Li Juan, Zhao Hailiang et al. Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials[J] BMC Endocrine Disorders, 2022, 22(1)

